טוען...
Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis
Cerivastatin, an HMG-CoA reductase inhibitor withdrawn from the market due to serious adverse effects, is metabolized primarily by CYP2C8. The occurrence of associated myotoxicity and rhabdomyolysis were attributed to altered cerivastatin pharmacokinetics due to gemfibrozil-inhibition or genetic var...
שמור ב:
| Main Authors: | , , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2010
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2993694/ https://ncbi.nlm.nih.gov/pubmed/20739906 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FPC.0b013e32833ecace |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|